Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Stock Surges 16.5 Percent on SynX Patent News

NEW YORK, Nov. 29 (GenomeWeb News) - Shares in Nanogen were up 16.46 percent, or $.65, in unusually heavy volume shortly after the company said its SynX subsidiary had won a European patent.


The stock was trading at $4.60 on the Nasdaq exchange mid-Monday as 2.9 million shares traded hands--a 350 percent increase over the average share volume for the past three months.


The patent, called "Method for Diagnosing and Distinguishing Stroke," covers a "diagnostic kit and method of measuring the presence of both an ischemic marker and a brain endothelial cell membrane protein to indicate that a patient has suffered a stroke and," Nanoge said in a statement. The IP is also designed to show "whether it was an ischemic or hemorrhagic cerebral event."


In October the US Patent and Trademark Office granted SynX a patent for "similar claims" related to the "rapid, point-of-care stoke diagnostic test that the company is developing for emergency medicine."


The patent covers a method and a diagnostic kit for analyzing the levels of proteins released from the brain during a neurovascular event. "By measuring the presence of an ischemic marker protein such as a myelin basic protein, S100 protein, neuronal specific enolase, or similar molecules, and a brain endothelial membrane protein such as thrombomodulin or a similar molecule, a physician can determine the occurrence of a stroke," Nanogen said.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.